周邊血單核細胞市場－全球產業規模、佔有率、趨勢、機會和預測，按產品、應用、技術、來源、地區和競爭細分，2020 年至 2030 年

2024年全球周邊血單核細胞市場價值為2.8089億美元，預計2030年將達到4.9602億美元，預測期內複合年成長率為10.02%。全球周邊血單核細胞市場正在經歷顯著成長，這得益於細胞療法數量的不斷成長、毒理學測試研發需求的不斷成長以及新產品穩定開發所需的化合物反應機制。例如，2023年6月，美國國家醫學圖書館發表的一項研究評估了體外感染克氏錐蟲哥倫比亞株（Col）並用苯並硝唑治療的周邊血單核細胞（PBMC）的免疫反應。

關鍵市場促進因素

政府資助的細胞療法和免疫學研究

主要市場挑戰

監管和品質合規的複雜性

主要市場趨勢

擴大在疫苗開發和免疫監測中的作用

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球周邊血單核細胞市場的影響

第5章：顧客之聲

第6章：全球周邊血單核細胞市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（冷凍保存或冷凍的 PBMC、培養或新鮮 PBMC 和周邊血單核細胞分離和活力試劑盒）
  • 按應用（免疫學、傳染病、血液學及其他）
  • 依技術（密度梯度離心法和白血球分離術）
  • 按來源（人類和動物）
  • 按地區（北美、歐洲、亞太、南美、中東和非洲）
  • 按公司分類（2024）
• 市場地圖
  • 按產品
  • 按應用
  • 依技術
  • 按來源
  • 按地區

第7章：北美周邊血單核細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第8章：歐洲周邊血單核細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第9章：亞太周邊血單核細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲

第10章：南美洲周邊血單核細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 11 章：中東和非洲周邊血單核細胞市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非

第 12 章：市場動態

• 驅動程式
• 挑戰

第13章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品/服務的威脅

第 15 章：SWOT 分析：全球周邊血單核細胞市場

第 16 章：臨床試驗分析

第 17 章：競爭格局

• Charles River Laboratories International, Inc.
• Lonza Group AG
• Corning Inc.
• Bio-Rad Laboratories Inc.
• ABCAM
• Biolegend Inc.
• ZEN-Bio Inc.
• DAPCEL, Inc.
• Creative Bioarray
• iXCells Biotechnologies USA, LLC

第 18 章：策略建議

第19章調查會社について,免責事項

Global Peripheral Blood Mononuclear Cells Market was valued at USD 280.89 million in 2024 and is expected to reach USD 496.02 million by 2030 with a CAGR of 10.02% during the forecast period. The global market for Peripheral Blood Mononuclear Cells is experiencing significant growth, driven by the rising rate in number of cell therapies, high demand of research and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products. For instance, in June 2023, a study published in National Library of Medicine, it assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.

Key Market Drivers

Government-Funded Cell Therapy and Immunology Research

Governments worldwide are significantly increasing investments in cell and gene therapy, where PBMCs play a critical role. In the U.S., the National Institutes of Health (NIH) continues to back programs-such as immuno-oncology and vaccine research-that rely heavily on PBMC-based assays to characterize immune responses before and after experimental treatments. NIH-funded vaccine programs studying T-cell immunity routinely isolate PBMCs from donors to quantify immunogenicity in clinical testing. Similarly, in Europe, the Innovative Medicines Initiative (IMI)-a €2 billion public-private partnership co-funded by the European Commission-supports drug development platforms that use PBMC-based biomarker identification and immune monitoring in early-phase clinical trials. This large-scale public-sector support for PBMC-integrated therapeutics research underlines PBMCs' indispensable role in translational medicine and offers a robust, policy-backed driver for market expansion.

Key Market Challenges

Regulatory and Quality Compliance Complexity

A significant challenge arises from the stringent and fragmented regulatory frameworks governing PBMC collection, processing, and distribution across jurisdictions. In the European Union, PBMC isolation facilities must conform to EU Tissue and Cells Directives (EUTCD) as well as national regulatory agency audits (e.g., Germany's Paul-Ehrlich-Institut), with repeat compliance checks and data privacy enforcement under GDPR-violations can incur fines exceeding €20 million. In China, PBMC processing kits are treated as Class III medical devices requiring clinical validation, and export of PBMC samples with human genetic information is restricted under the 2021 Biosecurity Law, mandating dual approvals from NMPA and the Ministry of Commerce. These variable, complex regulations raise costs for cross-border research and discourage adoption in regions without harmonized oversight, inhibiting global standardization and scalable PBMC usage.

Key Market Trends

Expanding Role in Vaccine Development and Immuno-Monitoring

A rapidly emerging trend is the expanded application of PBMCs for vaccine research and immunogenicity evaluation, especially in government-backed vaccine rollouts and pandemic preparedness. PBMCs offer critical insight into T-cell responses, cytokine profiles, and durability of immune memory. Governments funding large-scale vaccine trials-for diseases like COVID-19, malaria, tuberculosis-routinely incorporate PBMC-based assays into protocols to evaluate safety and immune efficacy. This creates predictable public-sector demand for standardized PBMC isolation, storage, and testing services, accelerating market growth tied to national immunization programs.

Key Market Players

• Charles River Laboratories International, Inc.
• Lonza Group AG
• Corning Inc.
• Bio-Rad Laboratories Inc.
• ABCAM
• Biolegend Inc.
• ZEN-Bio Inc.
• DAPCEL, Inc.
• Creative Bioarray
• iXCells Biotechnologies USA, LLC

Report Scope:

In this report, the Global Peripheral Blood Mononuclear Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peripheral Blood Mononuclear Cells Market, By Product:

• Cryopreserved or Frozen PBMC
• Cultured or Fresh PBMC
• Peripheral Blood Mononuclear Cell Isolation & Viability Kits

Peripheral Blood Mononuclear Cells Market, By Application:

• Immunology
• Infectious Disease
• Hematology
• Others

Peripheral Blood Mononuclear Cells Market, By Technique:

• Density Gradient Centrifugation Process
• Leukapheresis

Peripheral Blood Mononuclear Cells Market, By Source:

• Human
• Animals

Peripheral Blood Mononuclear Cells Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peripheral Blood Mononuclear Cells Market.

Available Customizations:

Global Peripheral Blood Mononuclear Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Peripheral Blood Mononuclear Cells Market

5. Voice of Customer

6. Global Peripheral Blood Mononuclear Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC and Peripheral Blood Mononuclear Cell Isolation & Viability Kits)
  • 6.2.2. By Application (Immunology, Infectious Disease, Hematology and Others)
  • 6.2.3. By Technique (Density Gradient Centrifugation Process and Leukapheresis)
  • 6.2.4. By Source (Human and Animals)
  • 6.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 6.2.6. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Product
  • 6.3.2. By Application
  • 6.3.3. By Technique
  • 6.3.4. By Source
  • 6.3.5. By Region

7. North America Peripheral Blood Mononuclear Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technique
  • 7.2.4. By Source
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technique
      • 7.3.1.2.4. By Source
  • 7.3.2. Canada Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technique
      • 7.3.2.2.4. By Source
  • 7.3.3. Mexico Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technique
      • 7.3.3.2.4. By Source

8. Europe Peripheral Blood Mononuclear Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technique
  • 8.2.4. By Source
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technique
      • 8.3.1.2.4. By Source
  • 8.3.2. France Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technique
      • 8.3.2.2.4. By Source
  • 8.3.3. United Kingdom Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technique
      • 8.3.3.2.4. By Source
  • 8.3.4. Italy Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technique
      • 8.3.4.2.4. By Source
  • 8.3.5. Spain Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technique
      • 8.3.5.2.4. By Source

9. Asia-Pacific Peripheral Blood Mononuclear Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technique
  • 9.2.4. By Source
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technique
      • 9.3.1.2.4. By Source
  • 9.3.2. Japan Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technique
      • 9.3.2.2.4. By Source
  • 9.3.3. India Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technique
      • 9.3.3.2.4. By Source
  • 9.3.4. South Korea Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product
      • 9.3.4.2.2. By Application
      • 9.3.4.2.3. By Technique
      • 9.3.4.2.4. By Source
  • 9.3.5. Australia Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Product
      • 9.3.5.2.2. By Application
      • 9.3.5.2.3. By Technique
      • 9.3.5.2.4. By Source

10. South America Peripheral Blood Mononuclear Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Technique
  • 10.2.4. By Source
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technique
      • 10.3.1.2.4. By Source
  • 10.3.2. Argentina Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technique
      • 10.3.2.2.4. By Source
  • 10.3.3. Colombia Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technique
      • 10.3.3.2.4. By Source

11. Middle East and Africa Peripheral Blood Mononuclear Cells Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Product
  • 11.2.2. By Application
  • 11.2.3. By Technique
  • 11.2.4. By Source
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. UAE Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Product
      • 11.3.1.2.2. By Application
      • 11.3.1.2.3. By Technique
      • 11.3.1.2.4. By Source
  • 11.3.2. Saudi Arabia Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Product
      • 11.3.2.2.2. By Application
      • 11.3.2.2.3. By Technique
      • 11.3.2.2.4. By Source
  • 11.3.3. South Africa Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Product
      • 11.3.3.2.2. By Application
      • 11.3.3.2.3. By Technique
      • 11.3.3.2.4. By Source

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Merger & Acquisition (If Any)
• 13.2. Product Launches (If Any)
• 13.3. Recent Developments

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Peripheral Blood Mononuclear Cells Market

16. Clinical Trial Analysis

• 16.1. Ongoing Clinical Trials
• 16.2. Completed Clinical Trials
• 16.3. Terminated Clinical Trials
• 16.4. Breakdown of Pipeline, By Development Phase
• 16.5. Breakdown of Pipeline, By Status
• 16.6. Breakdown of Pipeline, By Study Type
• 16.7. Breakdown of Pipeline, By Region
• 16.8. Clinical Trials Heat Map

17. Competitive Landscape

• 17.1. Charles River Laboratories International, Inc.
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Lonza Group AG
• 17.3. Corning Inc.
• 17.4. Bio-Rad Laboratories Inc.
• 17.5. ABCAM
• 17.6. Biolegend Inc.
• 17.7. ZEN-Bio Inc.
• 17.8. DAPCEL, Inc.
• 17.9. Creative Bioarray
• 17.10. iXCells Biotechnologies USA, LLC

18. Strategic Recommendations

19. About Us & Disclaimer